Skip to main content
OFIX logo

OFIX

Orthofix Medical Inc.
$11.54 -0.18 (-1.54%) At close · Jul 8
Market Cap
$464.24M
Shares
40,421,652

Price & Indicators

20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$11.54 Open$11.54 Day$11.39–11.72 52W$8.85–16.99 Avg vol 30d457K Short int2.0M · 4.9% float · 4.7d Short vol62% Last earningsMay 5, 2026 DataJan 2020–Jul 2026 Filing10-Q · May 5
Equibles Rating blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Neutral Momentum Weak Sentiment Bearish Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 16.9 · calm Equity put/call 0.86
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg −12%
below
Price vs 50-day avg +9%
above
RSI (14) 65
neutral
MACD trend Positive
52-week position 33%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Weak
1-month return +19%
trailing
6-month return −22%
trailing
YTD return −24%
this year
Relative strength −30%
vs S&P · 6-mo
Sentiment
smart money
Bearish
Trend (MA cross) No cross
50d $11 › 200d $13 — 200d above 50d
Institutional flow Distributing
5 of 146 funds reported for Jun 30 · net -51.1K sh shares
Insider flow Distributing
Net -$377.4K over 90 days · 60% sells
Short interest Rising
4.94% of float · ▲ +2.3% MoM · 4.7 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
146 holders — mid 3-yr range
Squeeze score 54
elevated · 0–100
Fundamentals
Strong
Revenue growth +3%
Y/Y
Gross margin 69%
expanding
EPS growth +29%
Y/Y
Free cash flow $-26.9M
Buyback $8.4M
remaining
Balance sheet $75.0M
net debt
Quant / Vol
risk profile
Very High
Volatility 45%
annualized · 1-yr
Max drawdown −45%
past year
ATR 5.2%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Up next
Next earnings call
Aug 4, 2026 Est · unconfirmed · in 4 wks
FQ3-26 quarter ends
~Sep 23, 2026 Est
filed May 5, 2026
AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Technicals

      trend & momentum for long-term holders Neutral
      1 · 4 · 2
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      −12% Bearish
      Price vs 50-day avg
      +9% Bullish
      RSI (14)
      65 Neutral
      MACD trend
      Positive Bullish
      52-week position
      33% Neutral
      Volume (OBV)
      Confirms Neutral
      Market signals — smart money & positioning
      Bearish · 3 of 6
      Trend (MA cross) No cross
      50d $11 › 200d $13 — 200d above 50d
      Institutional flow Distributing
      5 of 146 funds reported for Jun 30 · net -51.1K sh shares
      Insider flow Distributing
      Net -$377.4K over 90 days · 60% sells
      Short interest Rising
      4.94% of float · ▲ +2.3% MoM · 4.7 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      146 holders — mid 3-yr range
      Price context
      position in its 52-week range
      52-wk low $9 Now $12 · 33% 52-wk high $17
      vs 200-day avg -12% vs 50-day avg +9%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Versus peers

      Medical Devices — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      OFIX
      Orthofix Medical Inc.
      this stock
      $464.24M -23.9% +2.9% 4.9%
      ABT
      Abbott Laboratories
      $164.43B -23.6% +5.7% 26.4 1.3%
      SYK
      Stryker Corp
      $125.40B -6.8% +11.2% 37.9 1.6%
      MDT
      Medtronic plc
      $105.46B -13.9% +8.4% 22.1 1.4%
      BSX
      Boston Scientific Corp
      $66.87B -53.0% +5.5% 18.8 2.0%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Reducing
      Holders
      146
      % held
      88.3%
      Reported
      5 of 146
      Top holder
      Engine Capital Management…
      Held Float
      View
      Held by Funds
      Fund positions
      169
      View
      Short & Settlement
      Short Interest Rising
      Shares short
      2.0M
      Days to cover
      4.7d
      Change
      +44.6K sh
      View
      Short Volume
      Short vol %
      62%
      As of
      Jul 9, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      293
      Value
      $2.9K
      As of
      Jun 11, 2026
      View
      Off-Exchange
      Off-exchange %
      33.6%
      Week of
      May 4, 2026
      Off-exch Lit
      View
      Smart Money
      Insider Trades Net selling
      Net (90d)
      -$377.4K
      Buyers / Sellers
      2 / 3
      Buyers Sellers
      View
      Financials
      Financials
      Revenue (FY)
      $822.3M
      Net income (FY)
      $-92.2M
      EPS diluted
      $-2.33
      View
      Buybacks
      Authorized
      $75.0M
      Remaining
      $8.4M
      Spent Remaining
      View
      Filings
      SEC Filings
      Latest
      8-K
      Filed
      Jul 2, 2026
      This year
      11
      View
      Proposed Sales
      Value
      $926.0K
      Shares
      66.7K
      Filed
      Dec 21, 2023
      View
      Earnings & Events
      Earnings Calls Upcoming
      Next call
      Aug 12, 2026
      Last call
      Jun 8, 2026
      View
      Investor Relations
      Latest news
      Orthofix to Participate in Upcomi…
      Published
      May 18, 2026
      Upcoming events
      1
      View

      Performance

      5D 20D 120D MTD YTD
      OFIX +26.3% +19.1% -22.1% +26.3% -23.9%
      SPY -0.2% +0.8% +7.4% -0.2% +9.3%
      vs SPY +26.4% +18.3% -29.5% +26.4% -33.2%

      Capital returns

      Buyback program · as of Sep 30, 2016
      Authorized
      $75.00M
      Spent (derived)
      $66.60M
      Remaining
      $8.40M
      Spent Remaining

      Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

      Key facts CIK 884624 CUSIP 68752M108 13F (30d) 6 filings 6 filers Visit website Investor relations